Business
Partial preliminary results for NIH study of AGS-v
Partial preliminary results for NIH study of AGS-v.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 7759F hVIVO plc 31 October 2018 \n\nHVIVO PLC\n(\"hVIVO\" or the \"Company\")\n \nNIH present partial preliminary results from the Phase I first-in-man study of AGS-v, a Universal mosquito-borne diseases vaccine candidate\n \n- National Institutes of Health (NIH) presented partial preliminary results for some of the primary endpoint evaluations at the American Society of Tropical Medicine and Hygiene's sixty-seventh annual conference, New Orleans, US\n- Based upon currently available data the Phase I study met Primary Objectives and Endpoints with regard to safety and humoral response\n- The remaining primary and secondary endpoints will be evaluated once the full and final data are available\n- Given favourable safety profile and results so far, the vaccine warrants further development\n \nLondon, UK, 31 October 2018: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, confirms that the National Institutes of Health (NIH), has presented partial preliminary results from the recently completed Phase I study of AGS-v at the American Society of Tropical Medicine and Hygiene's (ASTMH) sixty-seventh annual conference, New Orleans, US. \n \nThe presentation at the conference focused on safety and certain immunogenicity results of AGS-v, a mosquito saliva peptide vaccine in the randomized, double-blind, placebo-controlled Phase I trial.\n \nCertain primary objectives and endpoints met.\n \n- AGS-v did not cause any clinically significant adverse events\n- Observed increase in vaccine -specific IgG antibodies with adjuvant present which was long lasting\n \nAdditional assays of the immunogenicity response and in vitro virus killing are ongoing and will be reported in due course. These will enable determination of the remaining primary endpoint analysis related to immunogenicity, along with the secondary endpoints.\n \nGiven the safety profile of the vaccine observed in this study further development of the vaccine will continue.\n \nAGS-v is being developed by Imutex Limited, hVIVO's 49% joint venture with the S...